Who we are

Dr Robert G Feldman, MB, BS, PhD

Dr Robert Feldman has an invaluable combination of business, medical and research experience spanning two decades. A qualified medical practitioner, he obtained his medical degree in London, his PhD in the Netherlands, has worked at Harvard Medical School and held clinical and academic positions at Imperial College, London. Dr Feldman is a successful serial life science entrepreneur, having founded the UK vaccine company Microscience and antimicrobial company Vmax. He later went on to become CEO of hepatitis C therapeutic company, RioTech before establishing the European operations for the New York based company Paramount Biosciences, LLC. As Entrepreneur in Residence for Imperial Innovations, London, Dr Feldman also co-founded the spin-out company, Indigix. In 2010, he moved to New Zealand as Executive Director of Pacific Channel and subsequently founded his own life science consulting company, Line 5.

During his extensive and varied career, Dr Feldman has developed a breadth of medical and research expertise encompassing therapeutics, devices, diagnostics and functional preparations in the field of human health. He has also gained a deep understanding of business and product development, fundraising, venture and governance. In addition to Dr Feldman’s work in the UK and New Zealand, he has also engaged in business development activities in several other countries, including successful licensing deals in Europe, USA, Australia, Russia, South Korea and New Zealand.

He supports both early-stage and mature life science businesses. He actively performs due diligence for investors and engages in company troubleshooting, commercialising opportunities, strategic and business planning, business and product development, and operations. Alongside his work with Life Science New Zealand and Line 5, Dr Feldman is a non-executive director of Canterbury Scientific Ltd, chair of its Scientific Advisory Panel and head of the company’s CS Ventures initiative.